APO Research
Talk to an analyst

APO RESEARCH · REPORT

Kidney Cancer Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Kidney Cancer Therapy Market Outlook and Growth Opportunities 2026

29 December 2025192 pages

Choose your research edition.

Industry ResearchKidney Cancer Therapy Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Kidney Cancer Therapy Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Kidney Cancer Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Kidney Cancer Therapy Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Kidney Cancer Therapy Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Kidney Cancer Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Kidney Cancer Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Kidney Cancer Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Kidney Cancer Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Kidney Cancer Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Kidney Cancer Therapy market include Eisai, Novartis, Merck, Roche, Pfizer, Bayer, Amgen, Sun Pharmaceutical and Hikma Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Kidney Cancer Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Kidney Cancer Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Kidney Cancer Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Kidney Cancer Therapy market.

Kidney Cancer Therapy Segment by Company

Eisai

Novartis

Merck

Roche

Pfizer

Bayer

Amgen

Sun Pharmaceutical

Hikma Pharmaceuticals

Exelixis

Bristol-Myers Squibb

Aveo Pharmaceuticals

Kidney Cancer Therapy Segment by Type

Targeted Therapy

Immunotherapy

Surgery

Other

Kidney Cancer Therapy Segment by Application

Renal Cell Carcinoma (RCC)

Transitional Cell Carcinoma (TCC)

Kidney Cancer Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Kidney Cancer Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Kidney Cancer Therapy key companies, revenue, market share, and recent developments.

3. To split the Kidney Cancer Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Kidney Cancer Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Kidney Cancer Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Kidney Cancer Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney Cancer Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Kidney Cancer Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney Cancer Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Kidney Cancer Therapy industry.

Chapter 3: Detailed analysis of Kidney Cancer Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Kidney Cancer Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Kidney Cancer Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Kidney Cancer Therapy Industry Trends Table 2. Kidney Cancer Therapy Industry Drivers Table 3. Kidney Cancer Therapy Industry Opportunities and Challenges Table 4. Kidney Cancer Therapy Industry Restraints Table 5. Global Kidney Cancer Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Kidney Cancer Therapy Revenue Share by Company (2021-2026) Table 7. Global Kidney Cancer Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Kidney Cancer Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Kidney Cancer Therapy Company, Product Type & Application Table 10. Global Kidney Cancer Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Kidney Cancer Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Targeted Therapy Table 15. Significant Companies of Immunotherapy Table 16. Significant Companies of Surgery Table 17. Significant Companies of Other Table 18. Global Kidney Cancer Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Kidney Cancer Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Kidney Cancer Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Kidney Cancer Therapy Sales Value Share by Type (2021-2026) Table 22. Global Kidney Cancer Therapy Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Renal Cell Carcinoma (RCC) Table 24. Significant Companies of Transitional Cell Carcinoma (TCC) Table 25. Global Kidney Cancer Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Kidney Cancer Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Kidney Cancer Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Kidney Cancer Therapy Sales Value Share by Application (2021-2026) Table 29. Global Kidney Cancer Therapy Sales Value Share by Application (2027-2032) Table 30. Global Kidney Cancer Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Kidney Cancer Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Kidney Cancer Therapy Sales Value Share by Region (2021-2026) Table 33. Global Kidney Cancer Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Kidney Cancer Therapy Sales Value Share by Region (2027-2032) Table 35. Global Kidney Cancer Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Kidney Cancer Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Kidney Cancer Therapy Sales Value Market Share by Country (2021-2026) Table 38. Global Kidney Cancer Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Kidney Cancer Therapy Sales Value Market Share by Country (2027-2032) Table 40. Eisai Company Information Table 41. Eisai Business Overview Table 42. Eisai Kidney Cancer Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Eisai Kidney Cancer Therapy Product Portfolio Table 44. Eisai Recent Development Table 45. Novartis Company Information Table 46. Novartis Business Overview Table 47. Novartis Kidney Cancer Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Novartis Kidney Cancer Therapy Product Portfolio Table 49. Novartis Recent Development Table 50. Merck Company Information Table 51. Merck Business Overview Table 52. Merck Kidney Cancer Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Merck Kidney Cancer Therapy Product Portfolio Table 54. Merck Recent Development Table 55. Roche Company Information Table 56. Roche Business Overview Table 57. Roche Kidney Cancer Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Roche Kidney Cancer Therapy Product Portfolio Table 59. Roche Recent Development Table 60. Pfizer Company Information Table 61. Pfizer Business Overview Table 62. Pfizer Kidney Cancer Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Pfizer Kidney Cancer Therapy Product Portfolio Table 64. Pfizer Recent Development Table 65. Bayer Company Information Table 66. Bayer Business Overview Table 67. Bayer Kidney Cancer Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Bayer Kidney Cancer Therapy Product Portfolio Table 69. Bayer Recent Development Table 70. Amgen Company Information Table 71. Amgen Business Overview Table 72. Amgen Kidney Cancer Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Amgen Kidney Cancer Therapy Product Portfolio Table 74. Amgen Recent Development Table 75. Sun Pharmaceutical Company Information Table 76. Sun Pharmaceutical Business Overview Table 77. Sun Pharmaceutical Kidney Cancer Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Sun Pharmaceutical Kidney Cancer Therapy Product Portfolio Table 79. Sun Pharmaceutical Recent Development Table 80. Hikma Pharmaceuticals Company Information Table 81. Hikma Pharmaceuticals Business Overview Table 82. Hikma Pharmaceuticals Kidney Cancer Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Hikma Pharmaceuticals Kidney Cancer Therapy Product Portfolio Table 84. Hikma Pharmaceuticals Recent Development Table 85. Exelixis Company Information Table 86. Exelixis Business Overview Table 87. Exelixis Kidney Cancer Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Exelixis Kidney Cancer Therapy Product Portfolio Table 89. Exelixis Recent Development Table 90. Bristol-Myers Squibb Company Information Table 91. Bristol-Myers Squibb Business Overview Table 92. Bristol-Myers Squibb Kidney Cancer Therapy Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Bristol-Myers Squibb Kidney Cancer Therapy Product Portfolio Table 94. Bristol-Myers Squibb Recent Development Table 95. Aveo Pharmaceuticals Company Information Table 96. Aveo Pharmaceuticals Business Overview Table 97. Aveo Pharmaceuticals Kidney Cancer Therapy Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Aveo Pharmaceuticals Kidney Cancer Therapy Product Portfolio Table 99. Aveo Pharmaceuticals Recent Development Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Kidney Cancer Therapy Product Image Figure 2. Global Kidney Cancer Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Kidney Cancer Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Kidney Cancer Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Targeted Therapy Image Figure 8. Immunotherapy Image Figure 9. Surgery Image Figure 10. Other Image Figure 11. Global Kidney Cancer Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Kidney Cancer Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Kidney Cancer Therapy Sales Value Share by Type (2021-2032) Figure 14. Renal Cell Carcinoma (RCC) Image Figure 15. Transitional Cell Carcinoma (TCC) Image Figure 16. Global Kidney Cancer Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Kidney Cancer Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Kidney Cancer Therapy Sales Value Share by Application (2021-2032) Figure 19. Global Kidney Cancer Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Kidney Cancer Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Kidney Cancer Therapy Sales Value (2021-2032) & (US$ Million) Figure 22. North America Kidney Cancer Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Kidney Cancer Therapy Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Kidney Cancer Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Kidney Cancer Therapy Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Kidney Cancer Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Kidney Cancer Therapy Sales Value (2021-2032) & (US$ Million) Figure 28. South America Kidney Cancer Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Kidney Cancer Therapy Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Kidney Cancer Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Kidney Cancer Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Targeted Therapy
  • Immunotherapy
  • Surgery
  • Other
Applications
  • Renal Cell Carcinoma (RCC)
  • Transitional Cell Carcinoma (TCC)
Companies covered
  • Eisai
  • Novartis
  • Merck
  • Roche
  • Pfizer
  • Bayer
  • Amgen
  • Sun Pharmaceutical
  • Hikma Pharmaceuticals
  • Exelixis
  • Bristol-Myers Squibb
  • Aveo Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Kidney Cancer Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Kidney Cancer Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Kidney Cancer Therapy Market Dynamics
  1. 2.1 Kidney Cancer Therapy Industry Trends
  2. 2.2 Kidney Cancer Therapy Industry Drivers
  3. 2.3 Kidney Cancer Therapy Industry Opportunities and Challenges
  4. 2.4 Kidney Cancer Therapy Industry Restraints
3 Kidney Cancer Therapy Market by Company
  1. 3.1 Global Kidney Cancer Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Kidney Cancer Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Kidney Cancer Therapy Company Ranking (2024-2026)
  4. 3.4 Global Kidney Cancer Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Kidney Cancer Therapy Company Product Type and Application
  6. 3.6 Global Kidney Cancer Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Kidney Cancer Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Kidney Cancer Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Kidney Cancer Therapy Market by Type
  1. 4.1 Kidney Cancer Therapy Type Introduction
  2. 4.1.1 Targeted Therapy
  3. 4.1.2 Immunotherapy
  4. 4.1.3 Surgery
  5. 4.1.4 Other
  6. 4.2 Global Kidney Cancer Therapy Sales Value by Type
  7. 4.2.1 Global Kidney Cancer Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Kidney Cancer Therapy Sales Value by Type (2021-2032)
  9. 4.2.3 Global Kidney Cancer Therapy Sales Value Share by Type (2021-2032)
5 Kidney Cancer Therapy Market by Application
  1. 5.1 Kidney Cancer Therapy Application Introduction
  2. 5.1.1 Renal Cell Carcinoma (RCC)
  3. 5.1.2 Transitional Cell Carcinoma (TCC)
  4. 5.2 Global Kidney Cancer Therapy Sales Value by Application
  5. 5.2.1 Global Kidney Cancer Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Kidney Cancer Therapy Sales Value by Application (2021-2032)
  7. 5.2.3 Global Kidney Cancer Therapy Sales Value Share by Application (2021-2032)
6 Kidney Cancer Therapy Regional Value Analysis
  1. 6.1 Global Kidney Cancer Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Kidney Cancer Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Kidney Cancer Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Kidney Cancer Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Kidney Cancer Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Kidney Cancer Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Kidney Cancer Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Kidney Cancer Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Kidney Cancer Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Kidney Cancer Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Kidney Cancer Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Kidney Cancer Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Kidney Cancer Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Kidney Cancer Therapy Sales Value Share by Country, 2025 VS 2032
7 Kidney Cancer Therapy Country-level Value Analysis
  1. 7.1 Global Kidney Cancer Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Kidney Cancer Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Kidney Cancer Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Kidney Cancer Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Kidney Cancer Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Kidney Cancer Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Kidney Cancer Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai
  2. 8.1.1 Eisai Company Information
  3. 8.1.2 Eisai Business Overview
  4. 8.1.3 Eisai Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Kidney Cancer Therapy Product Portfolio
  6. 8.1.5 Eisai Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Kidney Cancer Therapy Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Kidney Cancer Therapy Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Roche Kidney Cancer Therapy Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Kidney Cancer Therapy Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Kidney Cancer Therapy Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 Amgen
  38. 8.7.1 Amgen Company Information
  39. 8.7.2 Amgen Business Overview
  40. 8.7.3 Amgen Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Amgen Kidney Cancer Therapy Product Portfolio
  42. 8.7.5 Amgen Recent Developments
  43. 8.8 Sun Pharmaceutical
  44. 8.8.1 Sun Pharmaceutical Company Information
  45. 8.8.2 Sun Pharmaceutical Business Overview
  46. 8.8.3 Sun Pharmaceutical Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sun Pharmaceutical Kidney Cancer Therapy Product Portfolio
  48. 8.8.5 Sun Pharmaceutical Recent Developments
  49. 8.9 Hikma Pharmaceuticals
  50. 8.9.1 Hikma Pharmaceuticals Company Information
  51. 8.9.2 Hikma Pharmaceuticals Business Overview
  52. 8.9.3 Hikma Pharmaceuticals Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hikma Pharmaceuticals Kidney Cancer Therapy Product Portfolio
  54. 8.9.5 Hikma Pharmaceuticals Recent Developments
  55. 8.10 Exelixis
  56. 8.10.1 Exelixis Company Information
  57. 8.10.2 Exelixis Business Overview
  58. 8.10.3 Exelixis Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Exelixis Kidney Cancer Therapy Product Portfolio
  60. 8.10.5 Exelixis Recent Developments
  61. 8.11 Bristol-Myers Squibb
  62. 8.11.1 Bristol-Myers Squibb Company Information
  63. 8.11.2 Bristol-Myers Squibb Business Overview
  64. 8.11.3 Bristol-Myers Squibb Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bristol-Myers Squibb Kidney Cancer Therapy Product Portfolio
  66. 8.11.5 Bristol-Myers Squibb Recent Developments
  67. 8.12 Aveo Pharmaceuticals
  68. 8.12.1 Aveo Pharmaceuticals Company Information
  69. 8.12.2 Aveo Pharmaceuticals Business Overview
  70. 8.12.3 Aveo Pharmaceuticals Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Aveo Pharmaceuticals Kidney Cancer Therapy Product Portfolio
  72. 8.12.5 Aveo Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst